All sponsors

Minghui Pharmaceutical (Hangzhou) Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS16
PHASE 3 / 2-37
RECRUITING11
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO11%

Delay Index: of 9 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Minghui Pharmaceutical (Hangzhou) Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
MHB018A
NCT06989918
P3Active, not recruitingThyroid Associated Ophthalmopathies1082026-12 (-2 mo)
MHB036C
NCT06373406
P1/2Active, not recruitingAdvanced Solid Tumor2002027-04 (+32 mo)
Interventional
NCT07257185
P3Active, not recruitingThyroid Eye Disease (TED)1502027-08-31
MHB009C for Injection
NCT07326488
P1/2RecruitingAdvanced Malignant Solid Tumor2002028-02
MH004 1.0% Ointment
NCT07682506
P3RecruitingVitiligo4052028-02-23
MHB039A
NCT06345482
P1/2Active, not recruitingAdvanced Solid Tumor1962028-04-01
MHB018A injection
NCT07622121
P3RecruitingThyroid Eye Disease, TED1352028-07
MHB018A
NCT07622108
P3RecruitingThyroid Eye Disease, TED842028-07
MHB018A injection
NCT07262476
P3RecruitingThyroid Eye Disease (TED)2582029-01-31
MHB046C
NCT06985355
P1/2RecruitingAdvanced Solid Cancer2002029-05
MHB036C for Injection
NCT07229599
P1/2RecruitingAdvanced Lung Cancer3002029-05
MHB088C for Injection
NCT07126665
P1/2RecruitingAdvanced Malignant Solid Tumor1162029-08
MHB036C for Injection
NCT07130383
P2RecruitingAdvanced Breast Cancer; Advanced Malignant Solid Tumor2102029-08
MHB042C for Injection
NCT07192107
P1/2RecruitingAdvanced Malignant Solid Tumor2002029-10
MHB048C for Injection
NCT07192120
P1/2RecruitingmCRPC (Metastatic Castration-resistant Prostate Cancer); Advanced Malignant Solid Tumor2002029-10
MHB018A injection
NCT07620405
P3Not yet recruitingThyroid Eye Disease (TED)2192030-01